First patient dosed in phase I/IIa clinical trial of ABI-110
ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.
(Image credit: AdobeStock/Cavan)
The first patient has been successfully dosed in the Phase I/IIa clinical trial of ABI-110, Avirmax Biopharma 's first gene therapy drug for the treatment of wet age-related macular degeneration (AMD) including polypoidal choroidal vasculopathy (PCV).
In the press release1, Shawn Liu, PhD, Chief Executive Officer of Avirmax Biopharma Inc. highlighted this step forward, saying, "We are thrilled to announce this significant milestone in the clinical investigation of ABI-110. ABI-110 has the potential to revolutionize the treatment landscape for Wet AMD and PCV."
ABI-110 has the potential to offer a more durable and effective solution than current treatment options by addressing the root causes of wet AMD at the genetic level.
According to the company, ABI-110, Avirmax Biopharma's proprietary gene therapy, utilizes an engineered capsid, AAV2.N54, to efficiently deliver therapeutic transgene to the macular retina. This approach aims to provide a long-lasting solution that goes beyond the limitations of current treatments. The Phase 1 clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of ABI-110 in patients with Wet AMD and PCV.1
